HUE040373T2 - Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra - Google Patents

Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra

Info

Publication number
HUE040373T2
HUE040373T2 HUE15754041A HUE15754041A HUE040373T2 HU E040373 T2 HUE040373 T2 HU E040373T2 HU E15754041 A HUE15754041 A HU E15754041A HU E15754041 A HUE15754041 A HU E15754041A HU E040373 T2 HUE040373 T2 HU E040373T2
Authority
HU
Hungary
Prior art keywords
treatment
linking agents
collagen fibers
improved cross
corneal ectasia
Prior art date
Application number
HUE15754041A
Other languages
English (en)
Inventor
Giovanni Cavallo
Edoardo Stagni
Marco Biondi
Piero Biondi
Original Assignee
Sooft Italia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sooft Italia S P A filed Critical Sooft Italia S P A
Publication of HUE040373T2 publication Critical patent/HUE040373T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE15754041A 2015-04-29 2015-04-29 Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra HUE040373T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2015/000117 WO2016174688A1 (en) 2015-04-29 2015-04-29 Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia
EP15754041.0A EP3288588B1 (en) 2015-04-29 2015-04-29 Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia

Publications (1)

Publication Number Publication Date
HUE040373T2 true HUE040373T2 (hu) 2019-03-28

Family

ID=53969406

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15754041A HUE040373T2 (hu) 2015-04-29 2015-04-29 Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra

Country Status (8)

Country Link
US (1) US10688196B2 (hu)
EP (1) EP3288588B1 (hu)
ES (1) ES2693254T3 (hu)
HU (1) HUE040373T2 (hu)
PL (1) PL3288588T3 (hu)
PT (1) PT3288588T (hu)
SI (1) SI3288588T1 (hu)
WO (1) WO2016174688A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A2 (en) 2012-03-29 2024-08-28 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2016174688A1 (en) 2015-04-29 2016-11-03 Sooft Italia Spa Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia
JP6933377B2 (ja) 2015-07-21 2021-09-08 アヴェドロ・インコーポレーテッドAvedro,Inc. 光増感剤を用いた眼の処置用システム及び方法
FR3099045B1 (fr) 2019-07-22 2021-07-30 Univ Jean Monnet Saint Etienne Procede de production d’une pluralite d’implants a partir d’une cornee humaine ou animale prealablement prelevee
EP4308161A1 (en) * 2021-03-19 2024-01-24 Ligi Tecnologie Medicali S.r.l. Ophthalmic preparations for photo-crosslinking reactions
CN115089732A (zh) * 2022-07-22 2022-09-23 复旦大学附属中山医院 用于增强角膜生物力学的光敏剂光黄素-环糊精包合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411115D0 (en) 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
AU2001249984B2 (en) 2000-02-11 2005-05-26 The General Hospital Corporation Photochemical tissue bonding
CN1753683B (zh) 2002-12-20 2010-05-26 视可舒研究公司 预防和治疗不良眼部病症的眼用制剂
US20080015660A1 (en) 2006-07-13 2008-01-17 Priavision, Inc. Method And Apparatus For Photo-Chemical Oculoplasty/Keratoplasty
ITRM20070356A1 (it) 2007-06-26 2008-12-27 Sooft Italia Srl Soluzione oculare sterile monouso e suo procedimento di produzione per il cross linking corneale del cheratocono
US20090149923A1 (en) 2007-12-07 2009-06-11 21X Corporation Dba Priavision, Inc. Method for equi-dosed time fractionated pulsed uva irradiation of collagen/riboflavin mixtures for ocular structural augmentation
IT1393402B1 (it) 2008-08-28 2012-04-20 Sooft Italia Spa Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
EP2253321A1 (en) 2009-05-06 2010-11-24 Roberto Pinelli Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique
BRPI1001009A2 (pt) * 2010-03-26 2012-01-24 De Souza Lima Acacio Alves Jr composições micro e nanoestruturadas para aplicação ocular no tratamento de ceratocone
DE102016107819B4 (de) 2015-04-27 2018-08-23 Ali Ölmez Abformlöffel
WO2016174688A1 (en) 2015-04-29 2016-11-03 Sooft Italia Spa Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia

Also Published As

Publication number Publication date
PT3288588T (pt) 2018-11-13
US10688196B2 (en) 2020-06-23
WO2016174688A1 (en) 2016-11-03
EP3288588B1 (en) 2018-08-15
ES2693254T3 (es) 2018-12-10
PL3288588T3 (pl) 2019-02-28
SI3288588T1 (sl) 2018-12-31
US20180236100A1 (en) 2018-08-23
EP3288588A1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL248804B (en) A water-based preparation for the treatment of dry eye
SI3288588T1 (sl) Izboljšana sredstva za prečno povezovanje kolagenskih vlaken za uporabo pri zdravljenju kornealne ektazije
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
HK1256164A1 (zh) 用於治療神經膠質瘤的製劑
PL3145511T3 (pl) Kompozycja do leczenia oka
HK1259181A1 (zh) 用於預防和治療眼痛的氨基次膦酸衍生物
IL246855A0 (en) Materials for use in the treatment of retinitis
LT3406258T (lt) Vaistas, skirtas podagros gydymui
SG11201710686PA (en) Hair treatment agent
GB201503967D0 (en) Biocompatible implants for use in tendon therapy
PT3229780T (pt) Composições oftálmicas para utilização no tratamento da síndrome de olhos secos
HK1244438A1 (zh) 高分子處理劑
SG11201901985XA (en) Keratin fiber treatment composition
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB201703171D0 (en) Dry eye treatment
HK1191172A2 (en) Magical noninvasive eyes beauty operative treatment